890850O
Avanti
18:1 DAP
Avanti Research™ - A Croda Brand
Synonym(s):
1,2-dioleoyl-3-dimethylammonium-propane (DODAP)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C41H77NO4
CAS Number:
Molecular Weight:
648.05
UNSPSC Code:
12352211
NACRES:
NA.25
form
liquid
packaging
pkg of 2 × 100 mg (890850O-200mg)
pkg of 1 × 25 mg (890850O-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O
General description
18:1 DAP is a cationic lipid, used for the preparation of cationic liposomes.
Application
18:1 DAP is suitable for:
- as a component of lipid bilayers
- in the formulation of stable nucleic acid lipid vesicles
- in the preparation and physicochemical characterization of antisense oligodeoxyribonucleotide (ODN)-containing folate (FA)-targeted or non-targeted liposomes
Packaging
5 mL Clear Glass Sealed Ampule (890850O-200mg)
5 mL Clear Glass Sealed Ampule (890850O-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12(Suppl), 3-3 (2013)
Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service